Skip to content
2000
Volume 15, Issue 32
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

There has been a decline in the number of new drugs registered over the past decade and regulatory concerns for safety as well as payer concerns for efficacy have focused attention on stratified medicine. Integration of pharmacogenetics into the drug development pipeline will contribute to the development of new stratified drugs. We describe here the concept of pipeline pharmacogenetics and its application throughout the phases of drug discovery. Pipeline pharmacogenetics enables the evaluation of the genetic contribution to safety potentially lowering barriers to registration as well as providing rationale for efficacy and enabling co-development of genetic in vitro diagnostics.

Loading

Article metrics loading...

/content/journals/cpd/10.2174/138161209789649538
2009-11-01
2025-05-06
Loading full text...

Full text loading...

/content/journals/cpd/10.2174/138161209789649538
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test